Journey Medical Corp (DERM) Stock Price, Quote & News

Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 480 434 6670

Website: journeymedicalcorp.com

Address:

9237 East Via de Ventura Boulevard, Suite 105, Scottsdale, United States

Tomasini Dec. 24 at 3:18 PM

$DERM how much is oracea going generic going to hurt?

1 · Reply

JFais Dec. 22 at 11:29 PM

🤝 $SNDX $DERM

0 · Reply

JFais Dec. 20 at 11:08 PM

$DERM Reminder that EV < 1x peak sales has been a sweet spot for entry for us the past few years (less of these setups out there after 2025's $XBI rebound)

0 · Reply

JFais Dec. 20 at 2:52 PM

$DERM (crickets on this one from X and elsewhere, typically a good sign)

0 · Reply

JFais Dec. 20 at 2:52 PM

$DERM (L) From Weekly Recap

0 · Reply

FinSUN Dec. 19 at 5:39 PM

$DERM better keep moving

0 · Reply

FinSUN Dec. 19 at 3:51 PM

$DERM it's exhausting... still keep my block.

0 · Reply

SuperGreenToday Dec. 19 at 12:14 AM

$DERM Share Price: $7.92 Contract Selected: Feb 20, 2026 $7.5 Calls Buy Zone: $0.63 – $0.77 Target Zone: $1.07 – $1.31 Potential Upside: 61% ROI Time to Expiration: 63 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

JFais Dec. 17 at 1:42 PM

$DERM (L) From October's Recap post (worth resharing)

0 · Reply

makrodimutross Dec. 16 at 5:59 AM

$FBIOP $FBIO $DERM Revised Oaktree terms in a nutshell: The maximum TTM Minimum Net Sales seems to no longer be capped at $80 million, and will start higher (minimum 60m EOY 2025, instead of 50m). The minimum net sales test threshold will only grow by 5m per Q, instead of the original 7.5m per Q, and as such, will reach the 80m requirement EOY 2026. Based on a combination of Journey's and analyst projections, the 60m 2025 threshold should be no problem, and 2026 is projected to be just under 100m in revenues. None of the new terms appear to be a default concern for Fortress (why would they amend it if they thought they would be?). Also important to note that there is currently only 29.5m outstanding under the loan. New warrants (600,000 total) were not a surprise (this is biotech), and it's one of the reasons I feel more comfortable in FBIOP over FBIO at this time. This class 1 on CUTX-101 was welcome news, and anticipated based on the recent Zydus conference call. GLTA

2 · Reply

Market Cap	216.00M
Revenue (ttm)	56.13M
Net Income (ttm)	-14.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26.14%
Debt to Equity Ratio	0.97

Volume	29,500
Avg Vol	188,306
Day's Range	N/A - N/A
Shares Out	27.14M
Stochastic %K	86%
Beta	0.80
Analysts	Strong Sell
Price Target	$13.50